Investigative Ophthalmology & Visual Science Cover Image for Volume 59, Issue 9
July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Fluorescence Lifetime Imaging Ophthalmoscopy (FLIO) in Non-exudative AMD
Author Affiliations & Notes
  • Lydia Sauer
    Ophthalmology and Visual Sciences, John A Moran Eye Center, Salt Lake City, Utah, United States
    Department of Ophthalmology, University Hospital Jena, Jena, Germany
  • Karl Andersen
    Geisinger Commonwealth School of Medicine, Scranton, Pennsylvania, United States
    Ophthalmology and Visual Sciences, John A Moran Eye Center, Salt Lake City, Utah, United States
  • Rebekah H Gensure
    Ophthalmology and Visual Sciences, John A Moran Eye Center, Salt Lake City, Utah, United States
  • Gregory S Hageman
    Ophthalmology and Visual Sciences, John A Moran Eye Center, Salt Lake City, Utah, United States
  • Martin Hammer
    Department of Ophthalmology, University Hospital Jena, Jena, Germany
  • Paul S Bernstein
    Ophthalmology and Visual Sciences, John A Moran Eye Center, Salt Lake City, Utah, United States
  • Footnotes
    Commercial Relationships   Lydia Sauer, None; Karl Andersen, None; Rebekah Gensure, None; Gregory Hageman, None; Martin Hammer, None; Paul Bernstein, None
  • Footnotes
    Support  NIH Grants EY11600 and EY 14800; Lowy Medical Research Institute; Research to Prevent Blindness
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 2625. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Lydia Sauer, Karl Andersen, Rebekah H Gensure, Gregory S Hageman, Martin Hammer, Paul S Bernstein; Fluorescence Lifetime Imaging Ophthalmoscopy (FLIO) in Non-exudative AMD. Invest. Ophthalmol. Vis. Sci. 2018;59(9):2625.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Age-related macular degeneration (AMD) is a leading cause of blindness in the western world. Fluorescence lifetime imaging ophthalmoscopy (FLIO), a novel retinal imaging modality, may be very helpful to identify AMD at early stages.

Methods : This multi-centered study was conducted in Jena, Germany and Salt Lake City, USA. 134 eyes of 98 patients with AMD (mean age: 73.6 ± 10.3 years) as well as a group of healthy controls were investigated. Using the Heidelberg Engineering FLIO, a 30° retinal field centered at the fovea was investigated. Fluorescence was excited at 473 nm and obtained from a short (SSC, 498-560 nm) and long (LSC, 560-720 nm) spectral channel. The mean fluorescence lifetime (tm) was calculated, obtained from a standardized grid and compared across regions of interest. Optical coherence tomography and fundus photographs were also recorded.

Results : In eyes with non-exudative AMD, FLIO shows a pattern of prolonged tm in the LSC, which is of ring- or doughnut-like shape. This pattern is usually visible if the pseudo-color range within the software is set from 300 to 500 ps and occurs in early stages of the disease. It is not demarcated by other retinal diseases. In the LSC, tm from the ring was 398 ± 95 ps, while foveal tm was 295 ± 99 ps. The difference between those regions (99 ± 60 ps, p<0.001) is larger than in healthy eyes.

Conclusions : FLIO detects a clear and typical pattern of prolonged fluorescence signals, which is likely AMD-associated. These changes are visible in early AMD-stages and not masked by the presence of other coexisting retinal diseases. These findings may be useful for early diagnosis and to distinguish AMD from other retinal diseases.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

 

FAF lifetime and intensity images from the Long Spectral Channel (560 – 720 nm) of two healthy eyes and two eyes with dry age-related macular degeneration (AMD).

FAF lifetime and intensity images from the Long Spectral Channel (560 – 720 nm) of two healthy eyes and two eyes with dry age-related macular degeneration (AMD).

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×